Literature DB >> 19597005

Antibiotic treatment of animals infected with Borrelia burgdorferi.

Gary P Wormser1, Ira Schwartz.   

Abstract

Despite resolution of the objective manifestations of Lyme disease after antibiotic treatment, a minority of patients have fatigue, musculoskeletal pain, and/or difficulties with concentration or short-term memory of uncertain etiology; these are called post-Lyme disease symptoms or, in more severe cases, post-Lyme disease syndrome or "chronic Lyme disease." Several recent studies in which Borrelia burgdorferi-infected animals were treated with antibiotic therapy have demonstrated the presence of PCR positivity for B. burgdorferi DNA in the absence of culture positivity. In mice that were treated with antibiotic therapy, residual spirochetes could be taken up by ticks during a blood meal and could be transmitted to SCID mice. These spirochetes are attenuated; their presence is not associated with either inflammation or disease. In this review the methodology and findings of these studies are critically analyzed, and the significance of the results with regard to human Lyme disease is evaluated, with special emphasis on whether these studies provide useful insights into post-Lyme disease syndrome. A serious methodological concern is the failure to consider the pharmacokinetic-pharmacodynamic properties of the antibiotic in choosing the dosage regimen used. We conclude that there is no scientific evidence to support the hypothesis that such spirochetes, should they exist in humans, are the cause of post-Lyme disease syndrome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19597005      PMCID: PMC2708393          DOI: 10.1128/CMR.00004-09

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  53 in total

1.  Response to meta-analysis of Lyme borreliosis symptoms.

Authors:  Eugene D Shapiro; Raymond Dattwyler; Robert B Nadelman; Gary P Wormser
Journal:  Int J Epidemiol       Date:  2005-11-30       Impact factor: 7.196

Review 2.  Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis.

Authors:  Allen C Steere; Sheryn M Angelis
Journal:  Arthritis Rheum       Date:  2006-10

3.  Comparative in vitro and in vivo susceptibilities of the Lyme disease spirochete Borrelia burgdorferi to cefuroxime and other antimicrobial agents.

Authors:  R C Johnson; C B Kodner; P J Jurkovich; J J Collins
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

4.  Course of Borrelia burgdorferi DNA shedding in urine after treatment.

Authors:  Elisabeth Aberer; Andreas R Bergmann; Anna-Maria Derler; Bruno Schmidt
Journal:  Acta Derm Venereol       Date:  2007       Impact factor: 4.437

5.  Persistent joint swelling and Borrelia-specific antibodies in Borrelia garinii-infected mice after eradication of vegetative spirochetes with antibiotic treatment.

Authors:  Heta Yrjänäinen; Jukka Hytönen; Karl-Ove Söderström; Jarmo Oksi; Kaija Hartiala; Matti K Viljanen
Journal:  Microbes Infect       Date:  2006-05-30       Impact factor: 2.700

Review 6.  A critical appraisal of "chronic Lyme disease".

Authors:  Henry M Feder; Barbara J B Johnson; Susan O'Connell; Eugene D Shapiro; Allen C Steere; Gary P Wormser; W A Agger; H Artsob; P Auwaerter; J S Dumler; J S Bakken; L K Bockenstedt; J Green; R J Dattwyler; J Munoz; R B Nadelman; I Schwartz; T Draper; E McSweegan; J J Halperin; M S Klempner; P J Krause; P Mead; M Morshed; R Porwancher; J D Radolf; R P Smith; S Sood; A Weinstein; S J Wong; L Zemel
Journal:  N Engl J Med       Date:  2007-10-04       Impact factor: 91.245

7.  The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.

Authors:  Gary P Wormser; Raymond J Dattwyler; Eugene D Shapiro; John J Halperin; Allen C Steere; Mark S Klempner; Peter J Krause; Johan S Bakken; Franc Strle; Gerold Stanek; Linda Bockenstedt; Durland Fish; J Stephen Dumler; Robert B Nadelman
Journal:  Clin Infect Dis       Date:  2006-10-02       Impact factor: 9.079

8.  Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.

Authors:  Paul G Ambrose; Sujata M Bhavnani; Christopher M Rubino; Arnold Louie; Tawanda Gumbo; Alan Forrest; George L Drusano
Journal:  Clin Infect Dis       Date:  2006-11-27       Impact factor: 9.079

9.  Anti-tumor necrosis factor-alpha treatment activates Borrelia burgdorferi spirochetes 4 weeks after ceftriaxone treatment in C3H/He mice.

Authors:  Heta Yrjänäinen; Jukka Hytönen; Xiao-yu R Song; Jarmo Oksi; Kaija Hartiala; Matti K Viljanen
Journal:  J Infect Dis       Date:  2007-04-06       Impact factor: 5.226

Review 10.  Diagnosis of lyme borreliosis.

Authors:  Maria E Aguero-Rosenfeld; Guiqing Wang; Ira Schwartz; Gary P Wormser
Journal:  Clin Microbiol Rev       Date:  2005-07       Impact factor: 26.132

View more
  30 in total

Review 1.  Critical analysis of treatment trials of rhesus macaques infected with Borrelia burgdorferi reveals important flaws in experimental design.

Authors:  Gary P Wormser; Phillip J Baker; Susan O'Connell; Andrew R Pachner; Ira Schwartz; Eugene D Shapiro
Journal:  Vector Borne Zoonotic Dis       Date:  2012-05-23       Impact factor: 2.133

2.  Remains of infection.

Authors:  Alan Barbour
Journal:  J Clin Invest       Date:  2012-06-25       Impact factor: 14.808

3.  Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy.

Authors:  Linda K Bockenstedt; David G Gonzalez; Ann M Haberman; Alexia A Belperron
Journal:  J Clin Invest       Date:  2012-06-25       Impact factor: 14.808

4.  Culture of the entire mouse to determine whether cultivable Borrelia burgdorferi persists in infected mice treated with a five-day course of Ceftriaxone.

Authors:  Charles S Pavia; Gary P Wormser
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

Review 5.  Lyme Borreliosis: Is there a preexisting (natural) variation in antimicrobial susceptibility among Borrelia burgdorferi strains?

Authors:  Emir Hodzic
Journal:  Bosn J Basic Med Sci       Date:  2015-07-08       Impact factor: 3.363

6.  Xenodiagnosis to detect Borrelia burgdorferi infection: a first-in-human study.

Authors:  Adriana Marques; Sam R Telford; Siu-Ping Turk; Erin Chung; Carla Williams; Kenneth Dardick; Peter J Krause; Christina Brandeburg; Christopher D Crowder; Heather E Carolan; Mark W Eshoo; Pamela A Shaw; Linden T Hu
Journal:  Clin Infect Dis       Date:  2014-02-11       Impact factor: 9.079

Review 7.  Update on persistent symptoms associated with Lyme disease.

Authors:  Carlos R Oliveira; Eugene D Shapiro
Journal:  Curr Opin Pediatr       Date:  2015-02       Impact factor: 2.856

8.  Dysregulation of CD4+CD25(high) T cells in the synovial fluid of patients with antibiotic-refractory Lyme arthritis.

Authors:  Nalini K Vudattu; Klemen Strle; Allen C Steere; Elise E Drouin
Journal:  Arthritis Rheum       Date:  2013-06

9.  Differentiation of reinfection from relapse in recurrent Lyme disease.

Authors:  Robert B Nadelman; Klára Hanincová; Priyanka Mukherjee; Dionysios Liveris; John Nowakowski; Donna McKenna; Dustin Brisson; Denise Cooper; Susan Bittker; Gul Madison; Diane Holmgren; Ira Schwartz; Gary P Wormser
Journal:  N Engl J Med       Date:  2012-11-15       Impact factor: 91.245

Review 10.  Review: unraveling Lyme disease.

Authors:  Linda K Bockenstedt; Gary P Wormser
Journal:  Arthritis Rheumatol       Date:  2014-09       Impact factor: 10.995

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.